Shareholders Foundation, Inc.

NASDAQ:FENC Investor Notice: Lawsuit Alleges Misleading Statements by Fennec Pharmaceuticals Inc.

A lawsuit was filed on behalf of investors in Fennec Pharmaceuticals Inc. (NASDAQ:FENC) shares over alleged securities laws violations.


San Diego, CA -- (SBWIRE) -- 09/15/2020 -- An investor, who purchased shares of Fennec Pharmaceuticals Inc. (NASDAQ: FENC), filed a lawsuit against Fennec Pharmaceuticals Inc. over alleged violations of Federal Securities Laws in connection with certain allegedly false and misleading statements.

Investors who purchased shares of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) have certain options and for certain investors are short and strict deadlines running. Deadline: November 02, 2020. NASDAQ: FENC investors should contact the Shareholders Foundation at or call +1(858) 779 - 1554.

On August 11, 2020, Fennec Pharmaceuticals Inc. disclosed that it had received a Complete Response Letter ("CRL") from the U.S. Food and Drug Administration ("FDA") regarding the Company's New Drug Application ("NDA") for PEDMARK, a formulation of sodium thiosulfate for intravenous administration for the ototoxicity associated with cisplatin chemotherapy. According to the CRL, "after recent completion of a pre-approval inspection of the manufacturing facility of [Fennec's] drug product manufacturer, the FDA identified deficiencies resulting in a Form 483, which is a list of conditions or practices that are required to be resolved prior to the approval of PEDMARK."

The plaintiff claims that between February 11, 2020 and August 10, 2020, the defendants failed to disclose to investors that the manufacturing facilities for PEDMARK, the Company's sole product candidate, did not comply with current good manufacturing practices, that, as a result, regulatory approval for PEDMARK was reasonably likely to be delayed, and that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Those who purchased shares of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) have certain options and should contact the Shareholders Foundation.

Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.